Evaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes
Open Access
- 1 March 2021
- journal article
- research article
- Published by Wiley in Practical Diabetes
- Vol. 38 (2) , 13-19
Abstract
The incidence of type 1 diabetes in children is growing and optimal treatment is needed to prevent or delay complications. Insulin degludec is a new basal insulin with ultra‐long effect. However, there are few published studies in children and adolescents.The first aim was to compare HbA1c levels in children and adolescents who received degludec from onset, to age/gender matched controls with other basal insulins. The second aim was to investigate HbA1c and total basal insulin dose, in patients who switched to insulin degludec from another basal insulin.Patients (n=251, 0–21 years) with type 1 diabetes, at Helsingborg Hospital, were divided into groups depending on insulin treatment. Data regarding basal insulin and HbA1c values were collected from medical records retrospectively.No significant differences in HbA1c levels were found between patients receiving degludec compared to age/gender matched controls (n=22) up to 12 months from onset. In patients who switched to degludec with HbA1c ≥70mmol/mol (n=38), median HbA1c levels decreased from 75 (70–130) to 74 (39–99; p=0.0143) after three months and to 70.5 (55–108; p=0.0290) after six months. For patients who switched from detemir to degludec (n=54) median daily basal insulin dosage reduced from 23.5 units to 22 units after six months treatment with degludec (p=0.0001). The same significance was not found for glargine.In our study, degludec has shown to be as effective in lowering HbA1c levels as other basal insulins in children and adolescents with type 1 diabetes. Degludec might be especially useful for patients with a poor metabolic control. However, further long‐term studies are needed. Copyright © 2021 John Wiley & Sons.Keywords
This publication has 21 references indexed in Scilit:
- Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric populationInternational Journal of Pediatric Endocrinology, 2018
- Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world dataCurrent Medical Research and Opinion, 2017
- Clinical use of insulin degludecDiabetes Research and Clinical Practice, 2015
- Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetesPediatric Diabetes, 2015
- Intensive glucose control versus conventional glucose control for type 1 diabetes mellitusCochrane Database of Systematic Reviews, 2014
- Diabetes in the young – a global view and worldwide estimates of numbers of children with type 1 diabetesDiabetes Research and Clinical Practice, 2014
- Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week ExtensionThe Journal of Clinical Endocrinology & Metabolism, 2013
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialThe Lancet, 2012
- Age at Onset and the Risk of Proliferative Retinopathy in Type 1 DiabetesDiabetes Care, 2010
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993